Plaur (plasminogen activator, urokinase receptor) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Plaur (plasminogen activator, urokinase receptor) Rattus norvegicus
Symbol: Plaur
Name: plasminogen activator, urokinase receptor
RGD ID: 620597
Description: Predicted to enable enzyme binding activity; protein domain specific binding activity; and signaling receptor binding activity. Involved in several processes, including epithelial cell differentiation involved in prostate gland development; skeletal muscle tissue regeneration; and spermatogenesis. Predicted to be located in cell surface. Predicted to be part of protein complex involved in cell-matrix adhesion and serine-type endopeptidase complex. Predicted to be active in plasma membrane. Biomarker of chronic obstructive pulmonary disease; myocardial infarction; and status epilepticus. Human ortholog(s) of this gene implicated in rheumatoid arthritis. Orthologous to human PLAUR (plasminogen activator, urokinase receptor); PARTICIPATES IN fibroblast growth factor signaling pathway; coagulation cascade pathway; complement system pathway; INTERACTS WITH (+)-schisandrin B; (S)-colchicine; 1-naphthyl isothiocyanate.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: Par; plasminogen activator urokinase receptor 3; plasminogen activator, urokinase receptor 3; Plaur3; U-PAR; uPAR; uPAR-2; uPAR-3; urinary plasminogen activator receptor 2; urinary plasminogen activator receptor 3; urokinase plasminogen activator receptor; urokinase plasminogen activator surface receptor
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2180,053,440 - 80,068,384 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl180,050,324 - 80,068,595 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx185,446,800 - 85,461,972 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0193,996,901 - 94,011,843 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0187,202,621 - 87,217,793 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0181,328,171 - 81,344,954 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl181,328,183 - 81,344,708 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0182,587,242 - 82,602,924 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4179,708,646 - 79,712,881 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1179,786,756 - 79,791,047 (+)NCBI
Celera174,507,638 - 74,521,525 (+)NCBICelera
Cytogenetic Map1q21NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (ISO)
(+)-schisandrin B  (EXP)
(S)-colchicine  (EXP)
(S)-nicotine  (ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (EXP)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2-butoxyethanol  (ISO)
2-hydroxypropanoic acid  (ISO)
2-palmitoylglycerol  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3,4-dichloroaniline  (ISO)
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (EXP,ISO)
aflatoxin B1  (ISO)
all-trans-retinoic acid  (ISO)
amiloride  (ISO)
ammonium chloride  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antirheumatic drug  (ISO)
aripiprazole  (ISO)
aristolochic acid A  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
benazepril  (EXP)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzo[b]fluoranthene  (ISO)
beta-naphthoflavone  (ISO)
bexarotene  (ISO)
biochanin A  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
butan-1-ol  (ISO)
butanal  (ISO)
butyric acid  (EXP)
cadmium atom  (ISO)
calcitriol  (ISO)
cannabidiol  (ISO)
capsaicin  (ISO)
carbon nanotube  (ISO)
chenodeoxycholic acid  (ISO)
chloroprene  (EXP)
chlorpyrifos  (ISO)
choline  (ISO)
chromium(6+)  (ISO)
cisplatin  (ISO)
cobalt dichloride  (ISO)
copper(II) sulfate  (ISO)
crocidolite asbestos  (ISO)
Cuprizon  (EXP)
curcumin  (ISO)
cycloheximide  (ISO)
cyclosporin A  (ISO)
daidzein  (EXP)
decabromodiphenyl ether  (EXP)
deoxycholic acid  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
dibutyl phthalate  (EXP)
diethylstilbestrol  (ISO)
dimethylarsinic acid  (ISO)
dimethylarsinous acid  (ISO)
dinophysistoxin 1  (ISO)
dioxygen  (EXP,ISO)
diuron  (ISO)
doxorubicin  (ISO)
endosulfan  (EXP)
entinostat  (ISO)
fenvalerate  (EXP)
fluoranthene  (ISO)
flutamide  (EXP)
folic acid  (ISO)
formaldehyde  (EXP)
fulvestrant  (ISO)
furan  (EXP)
genistein  (ISO)
gentamycin  (EXP)
hexestrol  (ISO)
hyaluronic acid  (ISO)
hydrogen peroxide  (ISO)
hydrogen sulfide  (ISO)
ifosfamide  (ISO)
irinotecan  (ISO)
L-methionine  (ISO)
lidocaine  (EXP)
lipopolysaccharide  (EXP,ISO)
lithocholic acid  (ISO)
malathion  (ISO)
mestranol  (ISO)
methoxychlor  (EXP)
methylarsonic acid  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monosodium L-glutamate  (ISO)
N-acetyl-L-cysteine  (ISO)
naphthalene  (ISO)
naphthalenes  (EXP)
nickel atom  (ISO)
nickel sulfate  (ISO)
nicotine  (ISO)
nitroglycerin  (EXP)
ochratoxin A  (EXP,ISO)
ofloxacin  (EXP)
okadaic acid  (ISO)
oleanolic acid  (ISO)
ouabain  (ISO)
oxaliplatin  (EXP)
ozone  (EXP,ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP)
PD 0325901  (ISO)
pentanal  (ISO)
pentane-2,3-dione  (EXP)
perfluorohexanesulfonic acid  (ISO)
phenytoin  (ISO)
phosgene  (ISO)
pinostrobin  (ISO)
piroxicam  (ISO)
potassium dichromate  (ISO)
pregnenolone 16alpha-carbonitrile  (ISO)
progesterone  (EXP,ISO)
propanal  (ISO)
quartz  (EXP)
quercetin  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
resveratrol  (ISO)
SB 203580  (ISO)
serpentine asbestos  (ISO)
sevoflurane  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (ISO)
sodium dodecyl sulfate  (ISO)
Soman  (EXP)
sotorasib  (ISO)
streptozocin  (EXP,ISO)
succimer  (ISO)
sunitinib  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (EXP,ISO)
tetrachloromethane  (EXP,ISO)
thalidomide  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
topotecan  (EXP)
trametinib  (ISO)
trichloroethene  (EXP)
triclosan  (ISO)
trimellitic anhydride  (ISO)
triptonide  (ISO)
tris(2-butoxyethyl) phosphate  (ISO)
undecane  (EXP)
ursolic acid  (ISO)
valproic acid  (ISO)
valsartan  (ISO)
vanadyl sulfate  (ISO)
vincaleukoblastine  (EXP)
vincristine  (EXP)
zinc atom  (ISO)
zinc(0)  (ISO)

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Differential Roles of uPAR in Peritoneal Ovarian Carcinomatosis. Al-Hassan NN, etal., Neoplasia. 2012 Apr;14(4):259-70.
2. Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects. Cancello R, etal., Obes Facts. 2011;4(1):17-25. Epub 2011 Feb 16.
3. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Cunningham O, etal., Glia. 2009 Dec;57(16):1802-14.
4. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. de Bock CE and Wang Y, Med Res Rev 2004 Jan;24(1):13-39.
5. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. Djoba Siawaya JF, etal., J Infect. 2008 May;56(5):340-7. Epub 2008 Mar 21.
6. Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo. Donadio AC, etal., Clin Exp Metastasis 2002;19(5):437-44.
7. Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate. Elfman F, etal., Differentiation 2001 Dec;69(2-3):108-20.
8. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected africans: a prospective study. Fourie CM, etal., Inflammation. 2012 Feb;35(1):221-9.
9. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
10. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
11. Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection. Gueler F, etal., J Immunol. 2008 Jul 15;181(2):1179-89.
12. The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis. Gustafsson A, etal., Biomark Insights. 2012;7:39-44. Epub 2012 Apr 10.
13. [Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease]. Han XD, etal., Zhonghua Jie He He Hu Xi Za Zhi. 2007 May;30(5):363-7.
14. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Haugaard SB, etal., Diabet Med. 2012 Apr;29(4):479-87. doi: 10.1111/j.1464-5491.2011.03513.x.
15. The urokinase receptor (uPAR) facilitates clearance of Borrelia burgdorferi. Hovius JW, etal., PLoS Pathog. 2009 May;5(5):e1000447. Epub 2009 May 22.
16. Gene expression changes of urokinase plasminogen activator and urokinase receptor in rat testes at postnatal stages. Huang DH, etal., Asian J Androl. 2007 Sep;9(5):679-83.
17. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. Huttunen R, etal., J Intern Med. 2011 Jul;270(1):32-40. doi: 10.1111/j.1365-2796.2011.02363.x. Epub 2011 Mar 21.
18. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. Kenichi M, etal., J Lab Clin Med. 2004 Aug;144(2):69-77.
19. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Kofoed K, etal., Eur J Clin Microbiol Infect Dis. 2008 May;27(5):375-83. Epub 2008 Jan 16.
20. Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population. Koga T, etal., Clin Exp Rheumatol. 2011 Sep-Oct;29(5):811-5. Epub 2011 Oct 31.
21. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. Lahtinen L, etal., Neuroscience. 2009 Sep 29;163(1):316-28. Epub 2009 Jun 12.
22. In vivo fluorescence-mediated tomography for quantification of urokinase receptor-dependent leukocyte trafficking in inflammation. Larmann J, etal., Anesthesiology. 2010 Sep;113(3):610-8.
23. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Lonnkvist MH, etal., Scand J Gastroenterol. 2011 Apr;46(4):420-7. Epub 2010 Nov 30.
24. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. May AE, etal., Blood. 2002 Nov 15;100(10):3611-7. Epub 2002 Jul 12.
25. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
26. Initial brain lesion size affects the extent of subsequent pathophysiological responses. Nagai N, etal., Brain Res. 2010 Mar 31;1322:109-17. Epub 2010 Feb 4.
27. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
28. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Pawlak K, etal., Am J Med Sci. 2010 Jan;339(1):5-9.
29. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study. Persson M, etal., Atherosclerosis. 2012 Feb;220(2):502-5. Epub 2011 Nov 9.
30. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
31. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
32. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. Rabbani SA, etal., FEBS Lett 1994 Jan 24;338(1):69-74.
33. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Rabna P, etal., Inflammation. 2010 Dec;33(6):374-80.
34. GOA pipeline RGD automated data pipeline
35. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
36. Toxoplasma gondii pneumonitis in patients infected with the human immunodeficiency virus. Schnapp LM, etal., Arch Intern Med. 1992 May;152(5):1073-7.
37. Plasminogen activator promotes recovery following spinal cord injury. Seeds N, etal., Cell Mol Neurobiol. 2011 Aug;31(6):961-7. Epub 2011 May 14.
38. The expression of fibrinolytic components in chronic paranasal sinus disease. Sejima T, etal., Am J Rhinol Allergy. 2011 Jan-Feb;25(1):1-6.
39. uPA, uPAR and TGFbeta(1) expression during early and late post myocardial infarction period in rat myocardium. Stavropoulou A, etal., In Vivo. 2010 Sep-Oct;24(5):647-52.
40. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia. Toldi G, etal., Clin Chem Lab Med. 2011 Nov;49(11):1873-6. Epub 2011 Jul 4.
41. Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models. Tygstrup N, etal., Biochem Biophys Res Commun 2002 Jan 11;290(1):518-25.
42. Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome. Tzanakaki G, etal., Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1157-62. Epub 2011 Oct 5.
43. Urokinase plasminogen activator receptor-deficient mice demonstrate reduced hyperoxia-induced lung injury. van Zoelen MA, etal., Am J Pathol. 2009 Jun;174(6):2182-9. Epub 2009 May 12.
44. Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size. Weinmann M, etal., Br J Cancer 2002 Apr 22;86(8):1355-61.
45. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. Wiersinga WJ, etal., J Immunol. 2010 Mar 15;184(6):3079-86. Epub 2010 Feb 8.
46. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing. Xia W, etal., J Orthop Res. 2003 Sep;21(5):819-25.
47. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Zhou H, etal., Thromb Res. 2009;123(3):537-42. Epub 2008 Aug 8.
48. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Zimmermann HW, etal., Liver Int. 2012 Mar;32(3):500-9. doi: 10.1111/j.1478-3231.2011.02665.x. Epub 2011 Oct 17.
Additional References at PubMed
PMID:1321734   PMID:12477932   PMID:12665524   PMID:14688365   PMID:15042374   PMID:15863511   PMID:15922359   PMID:18397859   PMID:19897580   PMID:21423176   PMID:21679692   PMID:22511755  
PMID:22773570   PMID:22984561   PMID:23376485   PMID:24815166   PMID:24935436   PMID:38161044  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2180,053,440 - 80,068,384 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl180,050,324 - 80,068,595 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx185,446,800 - 85,461,972 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0193,996,901 - 94,011,843 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0187,202,621 - 87,217,793 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0181,328,171 - 81,344,954 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl181,328,183 - 81,344,708 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0182,587,242 - 82,602,924 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4179,708,646 - 79,712,881 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1179,786,756 - 79,791,047 (+)NCBI
Celera174,507,638 - 74,521,525 (+)NCBICelera
Cytogenetic Map1q21NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381943,646,095 - 43,670,169 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1943,646,095 - 43,670,547 (-)EnsemblGRCh38hg38GRCh38
GRCh371944,150,247 - 44,174,321 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 361948,842,088 - 48,866,342 (-)NCBINCBI36Build 36hg18NCBI36
Build 341948,844,571 - 48,866,342NCBI
Celera1940,952,740 - 40,977,471 (-)NCBICelera
Cytogenetic Map19q13.31NCBI
HuRef1940,580,832 - 40,605,572 (-)NCBIHuRef
CHM1_11944,151,900 - 44,176,634 (-)NCBICHM1_1
T2T-CHM13v2.01946,467,757 - 46,492,325 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39724,161,857 - 24,175,393 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl724,161,909 - 24,175,393 (+)EnsemblGRCm39 Ensembl
GRCm38724,460,937 - 24,475,970 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl724,462,484 - 24,475,968 (+)EnsemblGRCm38mm10GRCm38
MGSCv37725,247,519 - 25,260,892 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36724,171,260 - 24,184,634 (+)NCBIMGSCv36mm8
Celera719,076,593 - 19,089,968 (+)NCBICelera
Cytogenetic Map7A3NCBI
cM Map710.92NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049555551,378,793 - 1,393,324 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049555551,378,505 - 1,393,395 (-)NCBIChiLan1.0ChiLan1.0
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11111,476,804 - 111,490,876 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1111,476,893 - 111,490,880 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1110,957,047 - 110,970,796 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01112,087,347 - 112,101,189 (+)NCBIROS_Cfam_1.0
UMICH_Zoey_3.11111,675,381 - 111,689,348 (+)NCBIUMICH_Zoey_3.1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440934916,493,551 - 16,503,390 (-)NCBIHiC_Itri_2
SpeTri2.0NW_004936706840,968 - 855,552 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl650,489,777 - 50,505,418 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1650,489,773 - 50,505,453 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2646,349,485 - 46,365,098 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.1637,161,957 - 37,191,867 (-)NCBIChlSab1.1ChlSab1.1chlSab2
Vero_WHO_p1.0NW_02366607316,711,568 - 16,734,916 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046249071,174,448 - 1,189,377 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046249071,174,648 - 1,188,919 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Plaur
102 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:286
Count of miRNA genes:154
Interacting mature miRNAs:171
Transcripts:ENSRNOT00000018222, ENSRNOT00000074985, ENSRNOT00000075167
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1554320Bmd1Bone mineral density QTL 112.20.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)150910886060548Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
2313062Bmd73Bone mineral density QTL 733.90.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)11148131282174945Rat
2313065Bss67Bone structure and strength QTL 673.10.0001tibia area (VT:1000281)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313069Bss68Bone structure and strength QTL 682.90.0001tibia size trait (VT:0100001)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313075Bss66Bone structure and strength QTL 663.40.0001tibia length (VT:0004357)tibia length (CMO:0000450)11148131282174945Rat
2313077Bss69Bone structure and strength QTL 693.50.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)11148131282174945Rat
2313092Bmd72Bone mineral density QTL 722.50.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)11148131282174945Rat
2313097Bss70Bone structure and strength QTL 703.50.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
1358359Sradr1Stress Responsive Adrenal Weight QTL 14.74adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)130882023123479925Rat
70225Bp58Blood pressure QTL 583.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132356093162846471Rat
1300172Bp172Blood pressure QTL 1723.56arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)13273727390665040Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
2313051Bss57Bone structure and strength QTL 573.70.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)143284731118944897Rat
2313059Bss55Bone structure and strength QTL 553.20.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313072Bss53Bone structure and strength QTL 534.30.0001tibia length (VT:0004357)tibia length (CMO:0000450)143284731118944897Rat
2313078Bss54Bone structure and strength QTL 543.50.0001tibia area (VT:1000281)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313094Bss58Bone structure and strength QTL 583.70.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)143284731118944897Rat
2313098Bmd70Bone mineral density QTL 703.60.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)143284731118944897Rat
2313099Bss56Bone structure and strength QTL 562.40.0001tibia size trait (VT:0100001)tibia midshaft endosteal cross-sectional area (CMO:0001716)143284731118944897Rat
2302059Pia36Pristane induced arthritis QTL 363.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)14333300288333002Rat
2313402Anxrr24Anxiety related response QTL 24aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)148963584144267916Rat
4889962Bss94Bone structure and strength QTL 943.8tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)14936146582174945Rat
1578649Bmd8Bone mineral density QTL 84.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)14939317294393172Rat
1578654Bss10Bone structure and strength QTL 104femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)149393172159356837Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)149393289199050459Rat
6903308Scl36Serum cholesterol QTL 3620.0125blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)15386304190532583Rat
4889919Bss86Bone structure and strength QTL 864.1tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)15389511782174945Rat
4889929Bss87Bone structure and strength QTL 876.7tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)15389511782174945Rat
61342Bp27Blood pressure QTL 273.40.0006arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)15673266898773277Rat
2300164Bmd44Bone mineral density QTL 445.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)156949932101949932Rat
2298545Neuinf8Neuroinflammation QTL 84.6nervous system integrity trait (VT:0010566)spinal cord beta-2 microglobulin mRNA level (CMO:0002125)157336763151090257Rat
1300121Hrtrt1Heart rate QTL 13.7heart pumping trait (VT:2000009)heart rate (CMO:0000002)165789093115540829Rat
7421628Bp361Blood pressure QTL 3610.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)166023617118608521Rat
631512Scl6Serum cholesterol level QTL 69.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)17219768090508767Rat
1358192Ept13Estrogen-induced pituitary tumorigenesis QTL 133.4pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)177494165122494165Rat
10054135Gmadr2Adrenal mass QTL 21.970.0129adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)177857876122857876Rat
1549903Bp267Blood pressure QTL 267arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)177876254106047988Rat
61344Bp29Blood pressure QTL 297.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)178350581123350581Rat
7411712Strs4Sensitivity to stroke QTL 48.7cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)178430536123430536Rat
61433Cia2Collagen induced arthritis QTL 25joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)17843075491209302Rat
1582234Gluco18Glucose level QTL 183.40.0003blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)178479925123479925Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2180,068,122 - 80,068,240 (+)MAPPERmRatBN7.2
Rnor_6.0181,344,693 - 81,344,810NCBIRnor6.0
Rnor_5.0182,602,663 - 82,602,780UniSTSRnor5.0
Celera174,521,264 - 74,521,381UniSTS
Cytogenetic Map1q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2180,068,015 - 80,068,210 (+)MAPPERmRatBN7.2
Rnor_6.0181,344,586 - 81,344,780NCBIRnor6.0
Rnor_5.0182,602,556 - 82,602,750UniSTSRnor5.0
Celera174,521,157 - 74,521,351UniSTS
RH 3.4 Map1821.2UniSTS
Cytogenetic Map1q21UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 1 2 4
Low 43 56 40 18 40 8 11 31 35 32 7 8
Below cutoff 1 1 1 39 6


RefSeq Acc Id: ENSRNOT00000074985   ⟹   ENSRNOP00000065210
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,052,971 - 80,068,384 (+)Ensembl
Rnor_6.0 Ensembl181,328,183 - 81,344,705 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000075167   ⟹   ENSRNOP00000063960
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,055,095 - 80,068,595 (+)Ensembl
Rnor_6.0 Ensembl181,328,183 - 81,344,708 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000108508   ⟹   ENSRNOP00000096785
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,050,324 - 80,064,482 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000117518   ⟹   ENSRNOP00000079441
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,050,324 - 80,068,381 (+)Ensembl
RefSeq Acc Id: NM_134352   ⟹   NP_599179
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,053,440 - 80,068,384 (+)NCBI
Rnor_6.0181,328,173 - 81,344,951 (+)NCBI
Rnor_5.0182,587,242 - 82,602,924 (+)NCBI
RGSC_v3.4179,708,646 - 79,712,881 (+)RGD
Celera174,507,640 - 74,521,522 (+)NCBI
RefSeq Acc Id: NP_599179   ⟸   NM_134352
- Peptide Label: precursor
- UniProtKB: P51573 (UniProtKB/Swiss-Prot),   P49616 (UniProtKB/Swiss-Prot),   O35771 (UniProtKB/Swiss-Prot),   Q7TN35 (UniProtKB/Swiss-Prot),   M0R6Z6 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000063960   ⟸   ENSRNOT00000075167
RefSeq Acc Id: ENSRNOP00000065210   ⟸   ENSRNOT00000074985
RefSeq Acc Id: ENSRNOP00000096785   ⟸   ENSRNOT00000108508
RefSeq Acc Id: ENSRNOP00000079441   ⟸   ENSRNOT00000117518
Protein Domains

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P49616-F1-model_v2 AlphaFold P49616 1-328 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13689795
Promoter ID:EPDNEW_R319
Type:multiple initiation site
Description:plasminogen activator, urokinase receptor
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.0181,328,159 - 81,328,219EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:620597 AgrOrtholog
BioCyc Gene G2FUF-60444 BioCyc
Ensembl Genes ENSRNOG00000037931 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOG00055032435 UniProtKB/Swiss-Prot
  ENSRNOG00060033011 UniProtKB/Swiss-Prot
  ENSRNOG00065033571 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000074985.4 UniProtKB/TrEMBL
  ENSRNOT00000075167.4 UniProtKB/TrEMBL
  ENSRNOT00000108508.1 UniProtKB/TrEMBL
  ENSRNOT00000117518.1 UniProtKB/TrEMBL
  ENSRNOT00055056030 UniProtKB/Swiss-Prot
  ENSRNOT00060057271 UniProtKB/Swiss-Prot
  ENSRNOT00065057690 UniProtKB/Swiss-Prot
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro CD59_antigen_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  LY6_UPA_recep-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Snake_toxin-like_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:50692 UniProtKB/Swiss-Prot
PANTHER PTHR10624:SF6 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam UPAR_LY6 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Plaur PhenoGen
RatGTEx ENSRNOG00000037931 RatGTEx
  ENSRNOG00055032435 RatGTEx
  ENSRNOG00060033011 RatGTEx
  ENSRNOG00065033571 RatGTEx
SMART SM00134 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF57302 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  UPAR_RAT UniProtKB/Swiss-Prot
UniProt Secondary O35771 UniProtKB/Swiss-Prot
  P51573 UniProtKB/Swiss-Prot
  Q7TN35 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-03-05 Plaur  plasminogen activator, urokinase receptor  Plaur3  plasminogen activator, urokinase receptor 3  Symbol and Name updated to reflect Human and Mouse nomenclature 737654 APPROVED
2004-02-11 Plaur3  plasminogen activator, urokinase receptor 3  uPAR-3  urinary plasminogen activator receptor 3  Symbol and Name updated to reflect Human and Mouse nomenclature 625702 APPROVED
2002-08-07 Plaur        Symbol and Name status set to provisional 70820 PROVISIONAL
2002-08-07 uPAR-3  urinary plasminogen activator receptor 3      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_expression expression induced during hepatocyte regeneration after liver injury 70249
gene_process enhances proteolytic activity of urokinase-plasminogen activator 729625
gene_process may be involved in fibrinolysis, tumor invasion and metastasis 634477
gene_transcript transcript has isoforms that arise from alternative splicing 634477